Max Healthcare [MAXHEALTH] Shines in Q4FY24: PAT Jumps 7%, Revenue Up 12% Amidst Strong Ancillary Growth
Max Healthcare Institute [MAXHEALTH] reports robust Q4FY24 results with consolidated PAT growing 7% year-on-year to ₹342 crore and revenue increasing by 12%. The company also recommended a final dividend of ₹2 per equity share.
Max Healthcare Institute [MAXHEALTH], a leading healthcare provider in India, has announced a strong financial performance for the fourth quarter of the fiscal year 2024 (Q4FY24). The company showcased significant growth across key financial metrics, underscoring its operational efficiency and expanding market footprint.
For Q4FY24, Max Healthcare's consolidated Profit After Tax (PAT) registered a healthy 7% year-on-year increase, reaching ₹342 crore. This impressive growth in profitability was complemented by a 12% surge in revenue compared to the same period last year. The company's network EBITDA also demonstrated solid expansion, growing by 8%, reflecting robust operational performance across its facilities.
A key driver for this positive performance has been the exceptional growth in Max Healthcare's ancillary services. Both Max Lab, its diagnostic arm, and Max@Home, offering home healthcare solutions, recorded strong double-digit growth during the quarter. This highlights the success of the company's strategy to diversify its service offerings and cater to a broader spectrum of healthcare needs beyond its traditional hospital network.
In a move that signals confidence in its ongoing financial health and commitment to shareholders, the board of directors has recommended a final dividend of ₹2 per equity share for the financial year. This dividend proposal is a testament to Max Healthcare's consistent profitability and dedication to delivering value to its investors. With a strategic focus on both core hospital services and innovative care delivery models, Max Healthcare [MAXHEALTH] continues to strengthen its position in India's dynamic healthcare sector.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.